Protest Trial: TXA vs Saline

Enrolling by invitation · Phase 3 · Has a placebo group

Conditions studied: Lung Transplant, Complications Surgical

In brief

To determine if endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients reduces bleeding risk.

Key facts

Study ID

NCT06422273

Run by

Corewell Health West

People needed

94

Starts

2024-04-16

Expected to finish

2027-12-30

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Single or double lung transplant recipients
• Patients >18 years old
• Willingness and ability to sign an informed consent for study participation

You may not qualify if…

• Platelet count (<50k/uL)
• INR (>1.6)
• Active bleeding
• Decompensated liver disease
• History of uremic bleeding or BUN >50
• Severe pulmonary hypertension (mean PA pressure >40 mmHg on RHC or estimated PA systolic pressure >62 mmHg on TTE within one year of procedure)
• Known bleeding disorder
• Allergy to TXA
• Prior history of severe TBBx-related airway bleeding requiring admission or advanced maneuvers for hemostasis (examples including intubation, bronchial artery embolization, surgical intervention)
• Contraindications to topical TXA
• Pregnancy
• Vulnerable populations
• Adults of limited English proficiency/non-English speakers

Where it is running

• Corewell Health West — Grand Rapids, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.